Artiva Biotherapeutics, Inc.
For the period ended Jun 30, 2026. Filed Aug 6, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 6, 2026
ARTV$4.06-3.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Stockholders’ Equity
(in thousands, except share data)
| COMMON STOCK · ADDITIONALPAID-IN · ACCUMULATEDOTHERCOMPREHENSIVE · ACCUMULATED · TOTALSTOCKHOLDERS’ | ||||||
|---|---|---|---|---|---|---|
| SHARES | AMOUNT | CAPITAL | GAIN (LOSS) | DEFICIT | EQUITY | |
| Balance at December 31, 2024 | 24,291,607 | $3 | $433,451 | $(129) | $(246,684) | $186,641 |
| Exercise of stock options | 26,834 | — | 138 | — | — | 138 |
| ESPP shares issued | 22,164 | — | 134 | — | — | 134 |
| Issuance of common stock in connection with restricted stock units | 22,514 | — | — | — | — | — |
| Stock-based compensation expense | — | — | 2,052 | — | — | 2,052 |
| Unrealized gain on investments, net | — | — | — | 129 | — | 129 |
| Net loss | — | — | — | — | (20,311) | (20,311) |
| Balance at March 31, 2025 | 24,363,119 | $3 | $435,775 | $— | $(266,995) | $168,783 |
| Issuance of common stock in connection with restricted stock units, net | 30,405 | — | (39) | — | — | (39) |
| Stock-based compensation expense | — | — | 1,549 | — | — | 1,549 |
| Unrealized gain on investments, net | — | — | — | 2 | — | 2 |
| Net loss | — | — | — | — | (21,254) | (21,254) |
| Balance at June 30, 2025 | 24,393,524 | $3 | $437,285 | $2 | $(288,249) | $149,041 |
| Balance at December 31, 2025 | 24,595,550 | $3 | $440,413 | $103 | $(330,549) | $109,970 |
| ESPP shares issued | 64,768 | — | 131 | — | — | 131 |
| Issuance of common stock in connection with restricted stock units, net | 56,354 | — | (210) | — | — | (210) |
| Stock-based compensation expense | — | — | 1,593 | — | — | 1,593 |
| Unrealized loss on investments, net | — | — | — | (121) | — | (121) |
| Net loss | — | — | — | — | (23,516) | (23,516) |
| Balance at March 31, 2026 | 24,716,672 | $3 | $441,927 | $(18) | $(354,065) | $87,847 |
| Exercise of stock options | 13,310 | — | 67 | — | — | 67 |
| ESPP shares issued | 3,568 | — | 7 | — | — | 7 |
| Public offering of common stock and issuance of pre-funded warrants, net of issuance costs | 23,871,526 | 2 | 282,722 | — | — | 282,724 |
| Issuance of common stock in connection with restricted stock units | 187,203 | — | — | — | — | — |
| Stock-based compensation expense | — | — | 1,865 | — | — | 1,865 |
| Unrealized loss on investments, net | — | — | — | (3) | — | (3) |
| Net loss | — | — | — | — | (25,005) | (25,005) |
| Balance at June 30, 2026 | 48,792,279 | $5 | $726,588 | $(21) | $(379,070) | $347,502 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.